CDK4/6 inhibitors such as palbociclib and ribociclib have been approved and are utilized in clinical practice as standard of care with hormonal therapy for hormone receptor-positive/HER2-negative metastatic breast cancer [65], reducing hormone receptor-activated cell cycle progression and the modulation of the tumor microenvironment [66]. The gene discussed is NR4A1; the disease is neoplasm.